Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Imran Zainal Abidin, Ciaran J. McMullan et al.|The Lancet|2025Cited by 77
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaı̈ez Zannad, Nicholas Ryan, Marc P. Bonaca et al.|The Lancet|2025Cited by 39
The effect of vericiguat on sudden cardiac death: insights from the VICTOR trialFrancesco Fioretti, Carla Cristina Vicente, Faı̈ez Zannad et al.|European Journal of Heart Failure|2026Cited by 1